.png)
Intravenous Immunoglobulin (IVIg) Market Outlook: Innovation, Access & Commercial Strategy (2024–2032)
The IVIg market, comprising life-saving plasma‑derived immunoglobulin therapies used in autoimmune, neurologic, and immunodeficiency conditions, continues its steady growth. From an estimated USD 11.4 billion in 2023, the market is projected to reach approximately USD 12.0 billion in 2024, with forecasts aiming for USD 17.5 billion by 2032, reflecting a solid compound annual growth rate (CAGR) of ~5.5%. Growth is driven by expanding therapeutic indications, growing healthcare infrastructure, and improvements in plasma collection and manufacturing.
Drivers Fueling Market Expansion
1. Broader Therapeutic IndicationsIVIg has held long-standing superiority in managing primary immunodeficiencies, idiopathic thrombocytopenic purpura, and chronic inflammatory demyelinating polyneuropathy. Recently, clinical success in rare neurologic syndromes, post-transplant antibody-mediated rejection, and severe infections has encouraged off-label adoption—driving volume and access in hospital formularies.
2. Emergence of Subcutaneous Immunoglobulin (SCIg)To enhance patient convenience and reduce acute care burden, SCIg options are gaining traction. B2B strategies involve dual…
